<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 231 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page230.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=231">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 231 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 231</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=231"><img src="../thumb/231.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Dermatologicals - 14.6                                                         2020-04 / 195

                                                                      WITH ALDARA YOUR PATIENTS
                                                                      HAVE EFFECTIVE SUSTAINED
                                       ACTINIC /    SUPERFICIAL    EXTERNAL
                                        SOLAR    BASAL CELL    GENITAL   CLEARANCE FOR AK, sBCC
                                       KERATOSIS  CARCINOMA  WARTS    AND EGW 1-4

       Contraindications: Pregn., lactat., young childr., SLE, concom.   ILOTYCIN-A, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  incr.in acne at init.of ther., decr.contact lens tol., do not donate bld.
       hepatotox.medic., porphyr.    Tretinoin.                   dur. ther.and x1 mnth.aft.cessat., avoid diet. supplem. contain.Vit.A,
       Side effects: GI disturbs., bact./fung.overgrowth. incl.enterocolit.&   Indications: Acne vulgaris.  concom.tetracycl.assoc. with benign IC-hypertens., explicit.explanat.
       pseudomembr.colit., uraem., hepatotox., tooth discol.& enamel hy-  (S3) CREAM, [P/S] H/13.12/171. 0,05%.  of pregn. risk & relev.contracept.meas.to pt., pregn. test.prior & dur.
       poplas.in childr., bld.dyscras., vit.defic., allerg.reacts., photosens.,   842605-002: 20 g, R126,68  ther., avoid other keratolyt./ exfoliat.agents, avoid UV expos., long
       onycholys., nail discolour., rais.IC-press.  (S3) GEL, [P/S] H/13.12/172. 0,05%.  term therapeut. use not intend.
       Special precautions: Liv.funct.impairm., childr. und.12 yrs., my-  842591-001: 20 g, R74,26  Drug interactions: Addit.effs.tox.effs.with vit.A incl.diet.supplem.
       asth.sympts.poss.aggrav.      Dosage: Wash area with non-irritat.soap then apply 2xdly to af-  See also MDR page 462.
       Drug interactions: Absorpt.reduc.by di-& trivalent cations eg Al/  fect.areas.  ROACCUTANE, Roche [P/S]
       bismuth/Ca/Fe/Mg & Zn, sod.bircarab.& colestipol reduc.absorpt.,   Contraindications: Ac.dermatit.partic.ac. eczema & rosacea.
       poss.dos. reduct.of anticoags., nephrotox.effs.exacerbat.by diuret., Li   Side effects: Trans.skin redden.& feel.of warmth/ slight sting.  Isotretinoin.
                                                                  Indications: Sev.recalcitr.nodul.acne unrespons. to convent.ther.
       & digox.conc.poss.incr., tox.effs.of ergot alkaloids & methotrex.incr.,   on applic.
       poss.antagon.in act. with penicill., effic.of OC’s poss.decr.  Special precautions: Discont./reduc.freq.if loc. irrit. warrants,   incl.system.antibiot.
                                                                  (S5) CAPS. R/13.4.2/118, 119.
       EPIDUO 0,1%/2,5%, Galderma [P/S]  avoid eyes/mouth & mucous membr., other top.meds., peel.agents   761125-020: 10 mg, 30, R272,49
                                     & abrasiv., sun expos.
       Adapalene 1 mg, benzoyl peroxide 25 mg/g                   761133-004: 20 mg, 30, R495,66
                                                                             nd
                                                                               rd
       Indications: Acne vulgaris where comedones, papules & pus-  MINERVA-35, (Aspen Pharmacare: Pharma) Bayer [P/S]  Dosage: Indiv. Start on 2  or 3  day of menstruat. Admin.with food
       tules are pres.               21 tabs: Cyproterone acetate 2 mg, ethinylestradiol 0,035 mg & 7   once or twice dly. Init: 0,5 mg/kg dly.with dos.rang.to 1,0 mg/kg/day.
       (S3) GEL. 44/13.12/0109       non-hormon.tabs.             Sev.dis.& trunc.acne: Up to 2,0 mg/kg/day. Incr. remiss.rates &
       720002-001: 30 g, R273,11     Indications: Androgen depend.acne, androgen depend.alopec.,   prevent relapse admin.cumulat. treatm. dos.120-150 mg/kg. Ther.
       Dosage: Treatm.durat.determ.by clinic.condit. Clinic.improvem.ap-  hirsut., contracept.  durat.in indiv. pts. varies as a funct.of dly dos. Compl.remiss. often
       pear 1-4 wks.aft.treatm.init.  (S4) TABS, 29/21.8.2/0685   achiev.by 16-24 wks. Reduc.dos.in cases of intol.admin.over a long.
       Apply once dly.to affect.area bef.retir.& aft.wash.  897311-004: 28, R146,42  durat. Maj.pts.achiev. compl. clear.of acne with sngl.treatm.course.
       Side-effects: Skin irrit./erythema/dryn./scal./ burn.& sting.peak.  Dosage: 1 tab.at same time dly.from 1st day of menstr. cycle.  Observe interv.of 8 wks.bef.admin.2nd.course.
       dur.1  wks., prurit., sunburn, allerg. contact dermatit., fac.swell.  Contraindications: Pregn., lactat., disturbs.of liv.funct., choles-  Contraindications Lactat., pregn./women intend. to become pregn./
         st
       Warnings and special precautions: In case of sens.apply non-  tat.jaund., Dubin-Johns.syndr., Rotor syndr., prev./exist.liv.tumours,   women of childbear.age unless effect.contracept.is used uninter-
       comedon.moisturis./less freq./ discont.in case of sev.irrit., safety &   thrombo-embol. process., sev.migraine, cerebro-vasc. insuffic.,   rupt.for 1 mnth.prior to ther., dur.& at least 1 mnth.aft. discont. ther.,
       effective.not stud.in childr.und.12 yrs., do not apply to broken skin,   sickle-cell anaem., breast/endometr.Ca., undiag. vag.bleed., sev.di-  pre-exist.hypervitaminos.A, hepat./ ren. insuff., excess.elev.bld.lipid
       avoid contact with eyes/mouth/ nostrils & muc.membr., discont.  abet., lipometabol. disturbs., hist.of herpes/otoscleros./itch./jaund.  values, concom. Vit.A /tetracycl., other keratolyt./exfoliat.agents,
       in case of sens., excess. expos. to sun & UV radiat.to be avoid,   of pregn., otoscleros.with deterior.in prev.pregn.  concurr.radiat.ther.with UV light, fruct.intol.
       bleach.& discolourat.poss.if contact made with col.mater. incl.hair,   Side effects: Coron.& ven.thrombos., CVA’s, hypertens., prolong.  Side effects: Teratogen., hepatotox., hepatit., depress., psychos., suicid.
       other retinoids/benzoyl peroxide & meds. with simil.mode of act.not   amenorrh., N&V, headache, mood chang., chang.in libido, weight   ideat./attempts & suicide, pseudotumor cerebri, incr.ser.triglyceride &
       to be used concur., poss addit.irrit.effs.with concom. desquamat./ir-  gain, skin pigmentat., poor contact lens tol., gall bladd. dis., vag.  cholest.lev., pancreatit., decr.HDL, elev.bld. gluc., gram+ mucocutan.bact.
       rit.& dry.agents, not to be used in pregn.& lactat., tetratogen.shown   candidias., GI-irrit., fluid retent., breast tightn.& tendern., benign   infects., anaem., incr.RBC sedimentat.rate, thrombocytopen., thrombo-
       in anim.with oral admin.      & malig.liv.tumours.         cytos., neutropen., lymphadenopathy, allerg.skin reacts., anaphylact. re-
                                                                  acts., hypersens., diab.mellit, hyperuricaem., anx., mood alterat., abnorm.
       GINETTE, Cipla Medpro [P/S]   Special precautions: Diabet., hypertens., varicose veins, phlebit.  behav., psychot.disord., headache, benign intracran.hypertens., convuls.,
                                     hist., otoscleros., multiple scleros., epilep., porphyr., tetany, chorea
       21 tabs: ethinyl oestradiol 0,035 mg, cyproterone acetate 2 mg/  minor, asthma, depress., fluid retent., risk of thrombos., excl.andro-  drowsin., blepharit., conjunctivit., dry eye, eye irrit., blurr.vis., cataract, col.
       tablet & 7 placebo tabs.      gen-produc.tumour/adren.enzyme defect if hirsutism is recent/in-  blindn., contact lens intol., corn.opacity, decr.night vis., keratit., papilloed.,
       Indications: Contracept.in anti-androg.ther., as adj.to ethinyl oestra-  tensif., bear in mind sex. steroids can promote growth of cert.horm.  photophob., imp.hear., vasculit., epitax., nas.dryn., nasopharyngit., bron-
       diol in idiopath.hirsutism, sev. acne esp.androgen-depend.  depend. tiss. & tumours, hypercholesterolaem., famil. hyperlipoprot.,   chosp., hoarsen., colit., dry throat, GI haemorrh.& haemorrhag.diarrh.,
       (S4) TABS, 33/21.8.2/0185     oligomenorrh., amenorrh., surg./ immobilisat., very rare indiv.me-  inflam. bowel dis., naus., chelit., dermatit., dry skin, loc. exfoliat., prurit.,
       897214-005: 28, 1 mnth.cal.pack, R135,58  tabol.disturbs.may decr.effic., adeq.alt.contracept.in the event of   erythemat., skin fragility, alopec., acne fulminans, acne aggravat., fac.
       Dosage: 1 tab.at same time dly.from 1st day of menstr. cycle.  miss. tab./vomit./diarrh./concom.antibiot.ther.  erythema, exanthema, hair disords., hirsut., nail dystrophy, paronych.,
       Contraindications: Pregn., recent evacuat.of hydatidiform mole until   Drug interactions: Anti-epilep.agents/antibiot./ barbit./rifam-  photosens.reacts., pyogen.granuloma, skin hyperpigmentat., incr.sweat.,
       urine & plasma gonadotrop. norm., lactat., known/suspect.breast Ca,   picin decr.effic., insulin & other hypoglyaem. requirem.may change.  arthralg., myalg., back pain (partic. adolesc.), arthrit., ligament/ tendon
       liv.dis., wast./malign.dis., thrombo-embol. disords./ hist., sev. chron.  calcificat., epiphys., premat.fus., exostos.(hyperostos.), reduc.bone den-
       depress., sickle-cell anaem., oestrog.depend.neoplasma, funct.ovar.   ORATANE, Litha [P/S] &  sity, tendonit., glomerulonephrit., incr. granulat.tiss. format., erythema
       cyst, Dubin-Johnson or Rotor syndr., lipometabol. disords., sev.liv.  Isotretinoin.  multiforme, Stev.-John.syndr., tox.epiderm.necrolys.
       funct.impairm., cerebrovasc. insuff., coron.arter.dis., deteriorat.oto-  Indications: Sev.recalcitr.nodul.acne & sev. inflammat. acne and   Special precautions: Incr.spontan.abort.risk, no pregn.until 1 mnth.
       scleros., prurit. hist.dur.prev.pregn., undiag.vag.bleed., herpes, recurr.  acne conglobata resist.to convent. therapy incl.syst.antibiot.  discont.of Roaccutane, poss. contracept.fail., consid.indiv.effic.of con-
       cholestat.jaund., porphyr., migraine, use in men & childr.  (S5) CAPS. 35/13.4.2/0375, 0376, 42/13.4.2/0460  tracept. methods esp.dur.first cycle of horm.contracept., use two reliab.
       Side effects: Breast chang., menstr.flow & libido chang., depress.  701469-001: 10 mg, 60, R301,72  forms of contracept.simultan., negat. pregn.test 11 days prior to ther.,
       moods, GI disturbs., dizzin., headache, skin reacts., vag.candidi-  701471-001: 20 mg, 60, R609,03  mnthly. pregn.test recomm.dur.ther., pt.to confirm contracept. meas.
       as., mass gain, periph. oed., hair pattern alterat., bld.dyscras., gall   722786-001: 40 mg, 30, R609,03  underst./willingn.to comply, only to be used by spec.physic., est.liv.
       bladd.obstruct., hepatit., coron.& ven.thrombos., CVA’s, hypertens.,   Dosage: Indiv.depend.on pts.weight & severity. Admin. with meals.   funct.bef.& 1 mnth. aft.start of treatm.subseq.at 3 mnth.interv., dis-
       carbohydr.& lipid metabol. chang., benign & malig.liv.tumours, liv.  Low dos.once dly.& high. dos. as sngl.or div.dos. Init: 0,5 mg/kg dly.  cont.if hepatit.susp., monit.for signs of depress & init.appropr.treatm.
       funct. impairm., incr.cerv.Ca risk, poor contact lens tol., vis. dete-  x2-4 wks until.respons.est. Maint: Contin.at 0,5 mg/kg dly.if respons.  if reqd., discont.ther.& screen pts with sympts.of pseudotum.cerebri
       riorat.in myopic pts.         good reduc.to 0,1 -0,2 mg/kg with intol. dur.init.ther. Incr.to 1,0 mg/  for papilloed.& ref.to neurolog.for furth.diagn.& care, monit.pts.with
       Special precautions: Excl.pregn.bef.init. ther., diab.mellit., tetany,   kg/day where init. respons.inadeq.& in partic.sev.cases if well toler.   dry eye syndr., refer pts.with vis. diffic.for ophthalm.exam., advise pts.
                                                                  of poss.decr. night vis., monit.vis.prob.caref., est.lipid profile prior to
                                     Admin.maint.ther. x12 wks.for 1  stage of ther. Observ.8-20 wk. in-
                                                  st
       hypertens., epilep., chorea, multip.scleros., ren.dysfunct., asthma,   terv. bef.admin.2nd.course.if necess.
       depress., varicose veins, card.dysfunct., gallbladd.dis., cont. lens.,   Contraindications: Pregn.& lactat., acitretin/ tretinoin & vit.A de-  ther.& mnthly.thereaft.dur.treatm., discont. ther.in case of uncontr.hy-
                                                                  pertriglyceridaem./ pancreatit. sympt., freq.monit.recomm.in diabet./
       obesity, condits.influenc.by fluid retent., consid. benef.-risk in en-  rivat.hypersens., hepat./ren. impairm., hypervitaminos. A, hyperlipi-  obesity/ alcohol./lipid metabol.disords., skelet. hyperostos.observ.by
       dometrios.& uter.fibroids, discont.in case of onset of migraine/sev.   daem., concom. vit.A/other retinoids & tetracycl., women of childbear.  X-rays, consid.benef.-risk ratio in case of bone chang.incl.report.pre-
       headache, sudd./grad.hear.or vis.loss, first sign of thrombo-embol.  potent.unless uninterrupt.effect. contracept.practis.x1 mnth.prior to   mat. epiphys.clos.when treatm.exceed.3 mnths., discont.in case of
       disords., surg./prolong.bedrest, persist.upper abdom.pain/hepatit./  ther./dur.& at least one mnth.aft.discont.  GI S&S incl.sev.haemorrh. diarrh., interv.at 8 wks.bef.repeat.treatm.,
       jaund., monit. BP, in hirsut.excl.androg.-produc.tumours & adren.   Side effects: Teratogen., jaund., hepatit., pancreatit., depress., psy-  rep. course only for definite relapse., avoid sun, adjuv. ther.with mild
       enzyme eff.1 , oligomenorrh., amenorrh., hypercholesterolaem.,   chot.sympts., suicid. behav., benign.IC hypertens., corneal cloud.&   topic.meds.admin.as reqd., do not share meds. (partic.females), return
             st
       hyperlipoproteinaem., addit. non-horm.contracept. dur.antibiot.ther.  night vis. impairm., skelet.hyperostosis, hypervitaminos. A, skin   unused meds. to pharm.at end of treatm., do not donate bld.x1 mnth.
       Drug interactions: Griseofulvin/rifampicin/cert. antibiot.& anti-ep-  reacts., nail dystrophy, incr.granulat.tiss. format., persist.hair thinn.,   aft.stopp., poss.trans.incr.in acne at init.of ther., avoid aggress.derma-
       ilep.decr OC effectiven., effic.of some anticoags./antidepress./anti-  revers.alopec., hirsut., acne fulmin., hyperpigmentat., photosens.,   bras.& cutan.las. treatm./ wax depilat.x5-6 mnths.aft.treatm., poss.
       diab.agents/ anti-hypertens./ß-blocks.& diurets.reduc., theophyll. &   sev.skin reacts.incl.erythema multiforme/Stev.-John.syndr. & tox.  decr. contact lens tol., reduc.tol.to vigour.phys. activ., contains sorbit.
       cyclospor.plasma conc.incr.   epiderm.necrolys., dry eyes, keratit., conjunctivit., bld.dyscras., incr.  Drug interactions: Vit.A incr.S/E., tetracycl.incr. intracran. hypertens.
                                     ser.triglycer./ cholester. lev., decr.HDL, naus., headache, haemat./
       ILOTYCIN TS, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  proteinur., imp.hear., loc./system. infects., musc.& joint pain, in-  SKINOREN ACNE CREAM, (Adcock Ingram) Bayer [P/S] &
       Erythromycin base.            flammat.bowel dis., hyperuricaem., lymphadenopathy, bronchosp.  Azelaic acid.
       Indications: Acne vulgaris gr.II & III.  most. with asthma hist.  Indications: Mild to mod.acne vulgar.
       (S4) SOL. M/20.1.6/80. 20 mg/ml.  Warnings and special precautions: Est.liv. funct. prior to ther./  (S1) ACNE CREAM. W/13.12/228. 200 mg/g.
       828874-018: 50 ml, R191,59    aft.1 mnth treatm.& as appropr. dur.treatm., est. lipid profile prior to   794171-001: 30 g, R217,46
       Dosage: Apply 2xdly.aft.wash.  ther. & thereaft.mnthly dur.treatm., incr.risk of lipometabol. disords.,   Dosage: Apply to cleans.affect.area 2xdly. Contin. applic.over cou-
       Side effects: Prim.irrit./allerg.contact dermatit.  pancreatit.risk with high serum triglycer., observ. for depress.discont.&   ple of mnths for best results with clin.exper.for applicat.of up to 1 yr.
       Special precautions: Antibiot.resist.organ. overgrowth, safety   init. appropr.treatm.if occurs, discont.in pres.of vis. changes/ sympts.  Reduc amnt & freq.if skin irrit occurs.
       in pregn.not est.             of inflammat.bowel dis/region. ileitis, diabet./fam.hist.thereof., trans.  Contraindications: Safety in pregn.& lactat.not est.
         References: 1. Krawtchenko N, et al. Br J Dermatol 2007; 157(Suppl.2):34-40. 2. Stockfleth E et al. Arch Dermatol/Vol 140, Dec 2004:1542. 3. Gollnick H, et al. Eur J Dermatol 2005; 15(5):374-381. 4. Edwards L, et al. Arch Dermatol 1998; 134:25-30.
         Scheduling status: S4 Proprietary name and dosage form: ALDARA Cream. Composition: Each 2,0 g cream pump contains 5 % Imiquimod (100 mg). ALDARA Cream Sachet. Composition: Each 250 mg cream sachet
         contains 5 % Imiquimod (12,5 mg). Preservatives: Methyl hydroxybenzoate 0.2 % m/m, Propyl hydroxybenzoate 0.02 % m/m, Benzyl alcohol 2 % m/m. Pharmacological classification: A 34 Other. Indications: ALDARA
         Cream is indicated for the topical treatment of superficial basal cell carcinoma (sBCC), and of external genital/perianal warts (condyloma acuminata) and clinically typical, non hyperkeratotic, nonhypertrophic actinic keratosis
         (AKs) on the face or scalp in adult patients. Registration number: 32/34/0541. Name and business address of the holder of the certificate of registration: iNova Pharmaceuticals (Pty) Ltd,. Co. Reg. No. 1952/001640/07,
         15e Riley Road, Bedfordview. Tel. No. 011 087 0000. www.inovapharma.co.za. For full prescribing information, refer to the package insert as approved by the SAHPRA (South African Health Products Regulatory Authority).
         Further information is available on request from iNova Pharmaceuticals. IN3635/20</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page230.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page226.html">226</a>&nbsp;&nbsp;&nbsp;<a href="page227.html">227</a>&nbsp;&nbsp;&nbsp;<a href="page228.html">228</a>&nbsp;&nbsp;&nbsp;<a href="page229.html">229</a>&nbsp;&nbsp;&nbsp;<a href="page230.html">230</a>&nbsp;&nbsp;&nbsp;<a href="page231.html">231</a>&nbsp;&nbsp;&nbsp;<a href="page232.html">232</a>&nbsp;&nbsp;&nbsp;<a href="page233.html">233</a>&nbsp;&nbsp;&nbsp;<a href="page234.html">234</a>&nbsp;&nbsp;&nbsp;<a href="page235.html">235</a>&nbsp;&nbsp;&nbsp;<a href="page236.html">236</a>
             </td>
             <td width="35%"><a href="page232.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page232.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
